Expedia Group Q3 2020 Earnings Release Available on Company’s IR Site

SEATTLE--(BUSINESS WIRE)-- Expedia Group, Inc. (NASDAQ: EXPE) posted its third quarter 2020 earnings release in the Investor Relations section of its corporate website at http://ir.expediagroup.com. The earnings release is also available on the Securities and Exchange Commission’s website at http://www.sec.gov. As announced previously, the company will host a conference call today to discuss financial results at 1:30 PM Pacific Time / 4:30 PM Eastern Time.

In addition to the earnings release, a live webcast of the conference call will be available to the public at http://ir.expediagroup.com. A replay of the call is expected to be available for at least three months.

About Expedia Group

Expedia Group (NASDAQ: EXPE) helps knock down the barriers to travel, making it easier, more enjoyable, more attainable and more accessible. We are here to bring the world within reach for customers and partners around the globe. We leverage our platform and technology capabilities across an extensive portfolio of businesses and brands to orchestrate the movement of people and the delivery of travel experiences on both a local and global basis. Our family of travel brands includes: Brand Expedia®, Hotels.com®, Expedia® Partner Solutions, Vrbo®, Egencia®, trivago®, HomeAway®, Orbitz®, Travelocity®, Hotwire®, Wotif®, ebookers®, CheapTickets®, Expedia Group™ Media Solutions, Expedia Local Expert®, CarRentals.com™, Expedia® CruiseShipCenters®, Classic Vacations®, Traveldoo®, VacationRentals.com and SilverRail™.

© 2020 Expedia, Inc., an Expedia Group company. All rights reserved. Trademarks and logos are the property of their respective owners. CST: 2029030-50

View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005577/en/

Investor Relations
[email protected]

Communications
[email protected]

Source: Expedia Group, Inc.

You May Also Be Interested In

• Hertz cuts guidance, announces notes and stock offerings, shares sink
• Femasys regains Nasdaq minimum bid price compliance
• FDA aligns with Cognition Therapeutics on Phase 3 DLB psychosis trial